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Abstract
The patient is a 60-year-old woman with a history of vertigo and seasonal allergies who
presented to the hospital with the chief complaint of headache. Radiological findings were
negative for intracranial abnormalities. The headache was due to trigeminal neuralgia. She had
concurrent complaints of anosmia and ageusia without fever, respiratory symptoms, or obvious
risk factors. However, it was determined to test the patient for coronavirus disease 2019
(COVID-19) infection despite extremely low clinical suspicion. Unfortunately, she was found to
be COVID-19 positive after she was discharged from the hospital while she remained
asymptomatic. There is currently a lack of published case reports describing COVID-19 patients
with the sole symptoms of anosmia and ageusia in the United States of America.
Categories: Internal Medicine, Infectious Disease, Pulmonology
Keywords: anosmia, loss of smell, covid-19, novel coronavirus, coronavirus, atypical coronavirus,
ageusia, loss of taste
Introduction
COVID-19, or coronavirus disease 2019, originated from Wuhan, China, in December 2019. It is
caused by novel enveloped single-stranded ribonucleic acid (RNA) betacoronavirus, which is
known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. This disease
has since quickly spread worldwide within a few months. The World Health Organization
(WHO) reports that there are a total of 1,353,361 global cases along with 79,235 total deaths as
of April 9, 2020 [2]. Typical symptoms include fever, cough, and shortness of breath [3]. While
these symptoms are the typical presentations, other symptoms are gaining more attention as
possible indicators of the disease as our understanding of the disease is rapidly evolving. These
atypical symptoms include olfactory and gustatory dysfunctions [4]. There is a lack of evidence
in the current medical literature of anosmia or ageusia in patients suspected of having COVID-
19 infection. The Center for Disease Control (CDC) currently does not include these findings as
symptoms of COVID-19 but does state that medical awareness should be increased in this
setting [3]. Likewise, the WHO does not include these symptoms as part of the differential
diagnosis but does mention that other unconventional symptoms, such as myalgia, nasal
congestion, runny nose, sore throat or diarrhea, do exist [5]. Physicians are sounding the alarm
to this lack of attention and evidence in the medical literature. This case report details a 60-
year-old woman with the chief complaint of right-sided headache along with anosmia and
ageusia but was eventually found to be SARS-COV-2 positive.
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Case Presentation
Our patient is a 60-year-old woman who presented to the emergency department (ED) with the
chief complaint of right-sided headache for the past week. She had a past medical history of
asthma, vertigo, seasonal allergies, and anxiety. Her headache was located predominantly at
the right temporal, retro-ocular, and retro-auricular regions. She described the headache as an
"electrical sensation" that was associated with occasional nausea, blurry vision in both eyes
accompanied by a metallic taste in the mouth with a loss of smell sensation. She denied any
fever, sore throat, rhinorrhea, cough, myalgia, vomiting, dysphagia, neck pain, chest pain,
shortness of breath, weakness, or sensory disturbances. The review of systems was otherwise
unremarkable. She had magnetic resonance imaging (MRI) in the outpatient setting last year
due to vertigo and the result was unremarkable. She was generally healthy otherwise and did
not take any medications except for occasional loratadine for seasonal allergies. She is
currently retired, lives at home, denies any smoking history or recent traveling. She was
recommended by her primary care physician (PCP) to take amoxicillin to treat for sinusitis as
the possible underlying cause of her symptoms. However, she elected to defer the treatment but
rather decided to present to the ED for further evaluation.
In the ED, her initial vital signs were: temperature 98.1°F, blood pressure 142/81 mmHg,
respiratory rate 18 breaths per minute, heart rate 84 beats per minute, and oxygen saturation
95% on ambient air. Physical examination was completely unremarkable. The only abnormal
laboratory results were: erythrocyte sedimentation rate (ESR) 31 mm/hr, alanine transaminase
(ALT) 31 U/L. Computed tomography (CT) head without contrast showed no acute intracranial
abnormality (Figure 1). Her headache was thought to be related to trigeminal neuralgia and was
prescribed Gabapentin 300 mg twice a day. There were also concerns for possible COVID-19
infection due to anosmia and ageusia but additional testing was deferred due to the lack of
fever, respiratory distress, and laboratory abnormalities. This decision was made upon
extensive discussion with the infectious disease specialist, as the clinical suspicion for COVID-
19 was extremely low because it could be related to her seasonal allergies. The patient remained
stable overnight.
FIGURE 1: CT head without contrast
No acute intracranial hemorrhage, extracerebral fluids collection, acute transcortical infarction,
midline shift, or mass effect
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CT: computed tomography
Her headache improved on Days 2-3 of hospitalization. MRI of the brain found stable extensive
white matter changes without acute ischemic findings (Figure 2). She was eventually placed in
airborne isolation and SARS-COV-2 was sent to rule out COVID-19 infection despite low
clinical suspicion. She was subsequently discharged from the hospital and was instructed to
self-quarantine given pending results. SARS-COV-2 came back to be positive after one day. She
was notified over the phone and was recommended to continue to self-quarantine and seek
medication attention if there are new symptoms.
FIGURE 2: MRI of the brain
Stable extensive white matter changes without the presence of acute infarction
MRI: magnetic resonance imaging
Discussion
The most common COVID-19 symptoms include fever (43.8% on initial presentation and 88.7%
during hospitalization), cough (67.8%), nasal congestion (4.8%), nausea or vomiting (5.0%), and
diarrhea (3.8%) based on a research study of 1099 patients from China. However, both anosmia
or ageusia were not mentioned as both common and atypical symptoms in this study.
Significant laboratory findings that were listed include lymphocytopenia, thrombocytopenia,
leukopenia, elevated C-reactive protein, creatinine kinase, and d-dimer [1]. However, there are
other, newly emerging initial presenting symptoms that were absent in the Chinese patients, as
COVID-19 spreads quickly across the globe. They include asymptomatic carriers and other
nonspecific symptoms that do not generally arouse suspicion of a possible COVID-19 infection.
Most hospitals in the United States utilize COVID-19 screening criteria that include cough,
fever, and/or respiratory distress. Unfortunately, these screening criteria may miss out on silent
carriers and those with atypical presentations. Furthermore, Italy and France surprisingly
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reported a large population of patients with symptoms of anosmia and/or ageusia in a COVID-
19 confirmed diagnosis. In a letter to the editor submitted to the journal Obesity, Jean-François
Gautier and Yann Ravussin stated that they have observed cases of anosmia in patients
following two to three days of fatigue and headache [4]. Epidemiologist Hendrik Streek
mentioned that two-thirds of the patients have anosmia and ageusia lasting several days in
Germany [6]. In addition, 30% of COVID-19 confirmed cases in South Korea have had the
primary initial symptom of anosmia [4]. One preliminary study from China by Mao et al.
reported that 5.1% of the patients with COVID-19 had anosmia and 5.6% had ageusia [7]. In
another study of 320 patients from Italy by Vaira et al., 19.4% of patients had chemosensory
dysfunction not associated with rhinitis or nasal obstruction. However, these data have been
underestimated as symptoms of anosmia and ageusia were not always addressed [8].
Our patient had a very low clinical suspicion of COVID-19 infection, as she was afebrile along
with no respiratory symptoms despite having anosmia and ageusia in the setting of headache
caused by trigeminal neuralgia. Fortunately, she was adequately tested given that cases of
atypical presentation have been reported in the past. Gane et al. described a similar case report
of a patient with positive COVID-19 who presented with isolated anosmia but was otherwise
asymptomatic [9].
There are a few hypothesized mechanisms of action on why COVID-19 patients may develop
anosmia and ageusia despite their association with SARS-CoV-2 not having been yet
established. It could be due to direct damage of the virus on olfactory and gustatory receptors
[8]. The nasal epithelium contains olfactory epithelium (OE) and olfactory sensory neurons
(OSNs). OE contains basal stem cells that are responsible for renewing sustentacular cells and
OSNs. It also contains microvillar cells and mucus-secreting Bowman’s gland cells.
Sustentacular cells structurally support sensory neurons, detoxify, and maintain the salt and
water balance. It is thought that SARS-CoV-2 infects cells through interaction between its
spike (S) protein and the angiotensin-converting enzyme 2 (ACE2) protein on target cells. This
interaction requires cleavage of the S protein by the cell surface protease TMPRSS2. Therefore,
ACE2 and TMPRSS2 are required for SARS-CoV-2 to infect cells [10]. The study of mouse and
human RNA sequencing datasets by Brann et al. showed that OE expresses two key genes
required for SARS-CoV-2 entry: ACE2 and TMPRSS2. OSNs, on the contrary, did not show any
gene expression. Sustentacular cells in OE express these genes at levels comparable to those
found in lung cells. Thus, it suggests that SARS-CoV-2 may infect OE that contains
sustentacular cells, leading to damage of OE and disturbing the function of OSN. Loss of
sustentacular cells and the inability to regenerate OE over time can result in long-lasting
anosmia. In addition, damage to microvillar cells in OE might alter iron gradients and thus
affect the function of sensory neurons. Damage to the Bowman’s gland cells could cause
disruption of the olfactory neuroepithelium. However, due to the relatively new identification
of SARS-CoV-2-associated anosmia, no formal experiments have been performed to explore
SARS-CoV-2’s influence on OE. Moreover, it is unclear whether the olfactory abnormality is
due to dysfunction in the higher-order olfactory structures. It has shown previously that viruses
including coronavirus can propagate to olfactory bulb or piriform complex even though the
exact mechanisms of action are unknown. It is also unclear whether the impact of SARS-CoV-2
on smell is responsible for the alteration in taste perception [10].
Even though the association of anosmia with SARS-CoV-2 is currently not well-known,
previous respiratory viruses, such as coronaviruses, have shown to cause problems with smell
receptors and have been associated with post-viral anosmia [11]. A very recent multicenter
European study reported that 11.8% of patients with SARS-CoV-2 presented with olfactory
dysfunction prior to other symptoms. There was also a high prevalence (around 85%) of
olfactory or gustatory dysfunction among those patients with SARS-CoV-2 [12]. 
Thus, further research on the prevalence, duration, and severity of anosmia and ageusia in
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patients with COVID-19 is needed, as it is important to guide the prompt diagnosis, treatment,
and prevention of COVID-19 in the setting of an ongoing pandemic.
Conclusions
The understanding of COVID-19 is rapidly evolving, as we are in the middle of an unforeseen,
ongoing pandemic. Symptoms of COVID-19 patients range widely from fever, respiratory
symptoms, to newly reported findings of anosmia and ageusia from South Korea, Italy, and
France. Awareness of a possible COVID-19 infection should be raised in patients with the sole
presentation of anosmia and ageusia despite the lack of published case reports or research
findings on its exact mechanisms of action. Extra attention is sometimes a game-changer for
patient care and safety especially as we are situated in uncharted territory. COVID-19
discoveries are being made every day and healthcare providers should closely follow its
footsteps to ensure the best care is delivered to all patients.
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